REG - Diaceutics PLC - Notice of Interim Results and Presentations

DiaceuticsAnnouncement

05/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230905:nRSE3187La&default-theme=true

RNS Number : 3187L  Diaceutics PLC  05 September 2023

 

Notice of Interim Results and Presentations

Belfast and London, 5 September 2023 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, today confirms that it will
announce its unaudited results for the six months ended 30 June 2023 on
Tuesday, 26 September 2023.

Analyst Presentation

A webinar presentation for analysts will be held at 10.00am on Tuesday, 26
September 2023 via the London Stock Exchange's SparkLive platform. Those
wishing to attend can register using the following link:

https://www.lsegissuerservices.com/spark/Diaceutics/events/3e138a9b-2f9d-4adf-b5e0-790cb1f39b49
(https://www.lsegissuerservices.com/spark/Diaceutics/events/3e138a9b-2f9d-4adf-b5e0-790cb1f39b49)

Investor Presentation

Peter Keeling (CEO), Nick Roberts (CFO) and Ryan Keeling (CIO) will also
provide a live presentation relating to the Company's results via the Investor
Meet Company platform on Tuesday 26 September 2023 at 4.30pm.

The presentation is open to all existing and potential shareholders and
registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor
(https://www.investormeetcompany.com/diaceutics-plc/register-investor)

 

Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 9.00am the day before the meeting or at any time during the live
presentation. Investors who already follow Diaceutics on the Investor Meet
Company platform will automatically be invited.

 

Enquiries:

 Diaceutics PLC  
 Peter Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Innovation Officer                 investorrelations@diaceutics.com
 Nick Roberts, Chief Financial Officer 

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma PR                                                Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the
commercialisation of their precision medicines, enabled by our proprietary
DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real-world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUPUWABUPWGWC